Johnson & Johnson (NYSE:JNJ) gained ground on Q3 results Tuesday.
The health-care products giant reported Tuesday sales topped $20.7 billion, an improvement of 1.9% over the prior-year quarter, when sales came in at $20.3 billion.
Net earnings registered $4.8 billion, compared to $3.9 billion in the prior-year, a jump of 22.9%. EPS totaled $1.81, or 25.9% better than the prior-year’s $1.44.
Consumer worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 1.3%, driven by NEUTROGENA beauty products and over-the-counter products including TYLENOL analgesics, international upper respiratory products and digestive health products, partially offset by lower sales of baby care products due to prior year U.S. re-launch activities.
Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 6.4% driven by STELARA (ustekinumab), for the treatment of a number of immune-mediated inflammatory diseases, DARZALEX (daratumumab), for the treatment of multiple myeloma, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer.
Said CEO Alex Gorsky, "Our third-quarter results represent strong performance, driven by competitive underlying growth in Pharmaceuticals and Medical Devices, as well as continued optimization in our Consumer business.
"As we look ahead, we remain confident in the strength of our broad-based business model, which is fueled by our disciplined portfolio management, focus on transformational innovation and dedicated employees around the world who position us for success today and well into the future."
Shares sailed forward $2.03, or 1.6%, to $132.75
Related Stories
